In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.

The solubility of drugs and drug-like compounds has been the subject of extensive studies aimed at finding a way to predict solubility from molecular structure. The aqueous solubility of a drug is an important factor that influences its absorption, distribution and elimination in the body. Poor aqueous solubility often causes a drug to appear inactive and may cause other biological problems. Compound solubility in DMSO represents another serious problem in early stages of drug discovery. An appreciation of the factors affecting a compound's DMSO solubility could help in predicting the storage conditions and appropriateness of compounds for primary bioscreening programs. In silico procedures for estimation of water and DMSO solubility represent extremely useful tools for the drug discovery practitioners. In this review, we provide a critical discussion of in silico models for the prediction of DMSO and water solubility of drug-like compounds used for virtual screening. We describe the main tendencies in the field, "booming" approaches and unsolved problems. A critical analysis of the accuracy and applicability of methods is provided.

Support Vector Machines (SVM) is a powerful classification and regression tool that is becoming increasingly popular in various machine learning applications. We tested the ability of SVM, in comparison with well-known neural network techniques, to predict drug-likeness and agrochemical-likeness for large compound collections. For both kinds of data, SVM outperforms various neural networks using the same set of descriptors. We also used SVM for estimating the activity of Carbonic Anhydrase II (CA II) enzyme inhibitors and found that the prediction quality of our SVM model is better than that reported earlier for conventional QSAR. Model characteristics and data set features were studied in detail.

Support Vector Machines (SVM) is a powerful classification and regression tool that is becoming increasingly popular in various machine learning applications. We tested the ability of SVM, in comparison with wellknown neural network techniques, to predict drug-likeness and agrochemical-likeness for large compound collections. For both kinds of data, SVM outperforms various neural networks using the same set of descriptors. We also used SVM for estimating the activity of Carbonic Anhydrase II (CA II) enzyme inhibitors and found that the prediction quality of our SVM model is better than that reported earlier for conventional QSAR. Model characteristics and data set features were studied in detail.